Why is Indoco Remedies falling/rising?

Recent Price Movement and Market Performance

Indoco Remedies’ stock has been under pressure in recent trading sessions, with a one-week decline of 7.73%, starkly contrasting with the Sensex’s marginal fall of 0.55%. Over the past month, the stock has lost 7.64%, while the broader market gained 1.74%. Year-to-date, the stock has plummeted 27.62%, whereas the Sensex has advanced by 8.35%. This trend extends over longer horizons as well, with the stock delivering negative returns of 24.67% over the last year and 37.78% over three years, while the Sensex posted gains of 3.87% and 36.16% respectively. Such consistent underperformance highlights investor scepticism about the company’s prospects.

On 09-Dec, the stock underperformed its sector by 4.28%, hitting an intraday low of ₹237.6, down 5.62%. The weighted average price indicates that most trading volume occurred near this low, signalling selling pressure. Additionally, Indoco Remedies is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—further emphasising a bearish technical outlook. Notably, delivery volumes surged by 258.04% on 08 Dec compared to the five-day average, suggesting increased investor participation, likely dominated by sellers.

Financial Weaknesses Weighing on Investor Sentiment

Fundamental challenges are at the core of Indoco Remedies’ share price decline. The company’s ability to service its debt is notably weak, with a Debt to EBITDA ratio of 4.18 times, indicating high leverage and potential liquidity risks. This is compounded by a Debt-Equity ratio of 1.02 times as of the half-year, reflecting a capital structure heavily reliant on debt financing.

Profitability metrics also paint a grim picture. The average Return on Equity (ROE) stands at a modest 9.06%, signalling limited returns generated on shareholders’ funds. More concerning is the company’s operating profit, which has contracted at an alarming annual rate of 185.53% over the past five years. Indoco Remedies has reported negative results for 12 consecutive quarters, underscoring persistent operational challenges.

Interest expenses have surged by 48.67% in the latest six-month period, reaching ₹50.68 crores, further straining the company’s financials. The Return on Capital Employed (ROCE) for the half-year is negative at -2.14%, indicating that the company is not generating adequate returns on its invested capital. These factors collectively contribute to a perception of elevated risk among investors.

Market Risks and Institutional Investor Behaviour

Indoco Remedies’ stock is considered risky relative to its historical valuations, with profits falling by a staggering 552.7% over the past year. This steep decline in profitability has translated into a 24.67% negative return for shareholders during the same period. Institutional investors, who typically possess superior analytical resources, have reduced their holdings by 0.77% in the previous quarter, now collectively owning 19.41% of the company. This reduction in institutional participation often signals diminished confidence in the company’s turnaround prospects.

The stock’s consistent underperformance against the benchmark indices over the last three years further dampens investor enthusiasm. Despite the broader market’s robust gains, Indoco Remedies has failed to deliver positive returns, reflecting structural issues that have yet to be resolved.

Conclusion: Why Indoco Remedies Is Falling

In summary, Indoco Remedies’ share price decline on 09-Dec is a reflection of deep-rooted financial and operational challenges. The company’s high leverage, negative operating profits, and deteriorating returns have eroded investor confidence. Coupled with consistent underperformance relative to market benchmarks and reduced institutional interest, the stock faces significant headwinds. Technical indicators reinforce the bearish sentiment, with the stock trading below all major moving averages and increased selling volumes near intraday lows.

Investors should approach Indoco Remedies with caution, considering the company’s ongoing struggles and the availability of potentially more attractive investment opportunities in the pharmaceutical sector and broader market.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →